U.S. Patent Office Grants American Bio Medica a Patent for Its Multiple Drug Test Card
HUDSON, N.Y.--(BW HealthWire)--Feb. 1, 1999--American Bio Medica Corporation (NASDAQ:ABMC - news) today announced that the U.S. Patent Office recently awarded the Company a patent on the multiple drug test card used in the ABMC Rapid Drug Screen(tm) family of products.
''This is another in a series of patents and trademarks awarded to American Bio Medica throughout the world,'' stated Stan Cipkowski, president and CEO of ABMC and inventor of the multiple drug test card.
''We are building a patent portfolio to protect our intellectual property rights, and currently have over 30 additional patents and trademarks pending worldwide.''
Cipkowski noted that ABMC's drug test card is competitive because it provides positive or negative results for each substance being screened in an all-inclusive system. He explained that this design does not require the test administrator to add reagents, use a pipette to transfer the urine sample, or mix, tilt, or stir the mixture - features which are necessary with the majority of drug tests currently available.
The ABMC Rapid Drug Screen family of products is the most secure and flexible total on-site drugs of abuse testing system on the market. Unrivaled for ease of use, the ABMC test generates results in five
minutes at government mandated sensitivity levels.
American Bio Medica Corporation develops, manufactures, and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target
the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen is proven to correlate 100% with the standard laboratory screening test.
chris |
